G-Pen (glucagon injection) + Lilly Glucagon (glucagon injection [rDNA origin])
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Trial Timeline
Mar 15, 2017 → Sep 25, 2017
NCT ID
NCT02656069About G-Pen (glucagon injection) + Lilly Glucagon (glucagon injection [rDNA origin])
G-Pen (glucagon injection) + Lilly Glucagon (glucagon injection [rDNA origin]) is a phase 3 stage product being developed by Xeris Pharmaceuticals for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02656069. Target conditions include Hypoglycemia, Diabetes Mellitus, Type 1.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02656069 | Phase 3 | Completed |
Competing Products
20 competing products in Hypoglycemia